Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer

Trial Profile

Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Roniciclib (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 01 Jul 2016 The trial was completed in France (end date: 2016-03-08).
    • 27 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 09 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top